Skip to main content

Table 1 Participant characteristics at study enrollment in Machinga, Nkhotakota, and Karonga Districts, in Malawi, 2014 (n = 452)

From: In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated Plasmodium falciparum malaria in Malawi, 2014

Characteristic

AL

ASAQ

Total (n = 338)

Site

Total (n = 114)

Machinga (n = 112)

Nkhotakota (n = 113)

Karonga (n = 113)

Age, months (median, range)*, †

31 (6, 58)

35 (7, 58)

27 (6, 57)

34 (6, 57)

38 (9, 59)

Male, n (%)*

176 (52.1)

67 (59.8)

49 (43.4)

60 (53.1)

45 (39.5)

Participant slept under ITN previous night, n (%)†, a

269 (81.5)

101 (91)

70 (64.2)

98 (89.1)

92 (84.4)

Weight (kg) (mean, SD)

11.3 (3.6)

11.9 (3.1)

11.3 (2.2)

10.7 (4.8)

11.7 (3.4)

Haemoglobin (g/dL) (mean, SD)

9.8 (2.3)

9.4 (3.2)

9.7 (1.8)

10.2 (1.5)

10.0 (1.9)

Anaemia (Hb ≤11.0 g/dL)

264 (78.1)

99 (88.4)

87 (77)

78 (69)

84 (73.7)

Parasitaemia (parasites/μL) (geometric mean, range)†, b

35,512 (1100, 394,400)

25,700 (1100, 198,000)

39,171 (1393, 394,400)

44,361 (2066, 265,750)

30,882 (1019, 274,908)

  1. All participants were eligible for enrollment based on initial parasitaemia (1000–200,000 parasites/μL); however, 26 (6.1 %) participants had parasitaemia higher than 200,000 parasites/μL according to slide reviews done after study completion
  2. * Significant difference between study arms (p < 0.05); significant difference between study sites (p < 0.05)
  3. aInsecticide-treated bed net
  4. bAsexual parasitaemia